Scholarlink

Background <p>DNA methylation has been proposed as a predictive biomarker. Cervical intraepithelial neoplasia grade 2 (CIN2) was historically the cut-off for surgical treatment, however it is increasingly managed with active surveillance, while there is currently no accurate way to predict which lesions will regress.</p> Methods <p>We performed the first Illumina 850k array on DNA from serial liquid based-cytology cervical samples from young women with CIN2 that were managed with active surveillance (n = 58). Linear regression identified differentially-methylated sites at baseline distinguishing regressors from non-regressors with persistent or progressive disease at 24-months. Associations with imminent regression and histological change were also evaluated.</p> Results <p>We identified three novel differentially-methylated sites; cg12754953 (<i>ALDH9A1</i>) methylation was significantly increased at baseline in non-regressors, cg18887759 (<i>MED25</i>) methylation was significantly lower in samples from women who regressed within the subsequent 12 months, and cg13556949 (<i>TULP2</i>) methylation increased over time between baseline and 12-months of follow-up in non-regressors as compared to regressors.</p> Conclusion <p>Methylation could help guide treatment decisions in women considering active surveillance of CIN2 lesions. <i>ALDH9A1</i>, <i>MED25</i> and <i>TULP2</i> may be implicated as genes with possible roles in host response to viral mechanisms. Larger prospective studies are needed to validate these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Methylation biomarkers in non-regressive cervical intraepithelial neoplasia grade 2 lesions: an epigenome wide association study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月11日

查看全文
  • Laura Burney Ellis,
  • Sarah J. Bowden,
  • Maria Paraskevaidi,
  • Deirdre Lyons,
  • Evangelos Paraskevaidis,
  • Anna-Barbara Moscicki,
  • James M. Flanagan,
  • Maria Kyrgiou

摘要

Background

DNA methylation has been proposed as a predictive biomarker. Cervical intraepithelial neoplasia grade 2 (CIN2) was historically the cut-off for surgical treatment, however it is increasingly managed with active surveillance, while there is currently no accurate way to predict which lesions will regress.

Methods

We performed the first Illumina 850k array on DNA from serial liquid based-cytology cervical samples from young women with CIN2 that were managed with active surveillance (n = 58). Linear regression identified differentially-methylated sites at baseline distinguishing regressors from non-regressors with persistent or progressive disease at 24-months. Associations with imminent regression and histological change were also evaluated.

Results

We identified three novel differentially-methylated sites; cg12754953 (ALDH9A1) methylation was significantly increased at baseline in non-regressors, cg18887759 (MED25) methylation was significantly lower in samples from women who regressed within the subsequent 12 months, and cg13556949 (TULP2) methylation increased over time between baseline and 12-months of follow-up in non-regressors as compared to regressors.

Conclusion

Methylation could help guide treatment decisions in women considering active surveillance of CIN2 lesions. ALDH9A1, MED25 and TULP2 may be implicated as genes with possible roles in host response to viral mechanisms. Larger prospective studies are needed to validate these findings.